SCYNEXIS(US:SCYX)2022-08-15 18:23Financial Data and Key Metrics Changes - SCYNEXIS reported net product revenues of $1.3 million for BREXAFEMME in Q2 2022, nearly doubling from $700,000 in Q1 2022 [47] - R&D expenses increased to $7.1 million in Q2 2022 from $4.7 million in Q2 2021, while SG&A expenses rose to $15.8 million from $12.8 million in the same period [47] - Cash and cash equivalents totaled $118.7 million as of June 30, 2022, compared to $112.4 million a year earlier [48] Business Line Data and Key Metrics Changes - BREXAFEMME prescriptions grew by 29% quarter-over-quarter, with over 5,100 prescriptions in Q2 2022 [21][14] - The number of healthcare providers (HCPs) prescribing BREXAFEMME increased by 25% quarter-over-quarter, reaching over 2,200 HCPs [20] Market Data and Key Metrics Changes - Coverage for BREXAFEMME reached over 109 million commercially insured lives, representing approximately 60% of the commercial universe [23] - The company aims to increase coverage to 65% by the end of 2023 [59] Company Strategy and Development Direction - SCYNEXIS is focused on expanding the labeling and use of BREXAFEMME, with a PDUFA date set for November 30, 2022, for recurrent VVC indication [11] - The company plans to build a broad antifungal franchise and has several upcoming catalysts in 2022 and beyond [10][52] - The strategy includes enhancing HCP and patient campaigns to drive adoption and awareness of BREXAFEMME [18][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing adoption of BREXAFEMME despite macroeconomic headwinds [9] - The company anticipates that the approval of the recurrent VVC indication will significantly enhance prescriber confidence and drive prescription growth [11][19] - Management highlighted the potential for BREXAFEMME to generate $700 million to $800 million in annual net sales in the U.S. [52] Other Important Information - The company successfully raised $45 million in April 2022, providing a solid cash runway into Q1 2024 [15] - SCYNEXIS is conducting multiple studies, including the Phase 3b VANQUISH study and the MARIO study, to evaluate ibrexafungerp in various indications [12][43] Q&A Session Summary Question: What is the added market opportunity post-approval for recurrent VVC? - Management indicated that the new indication will provide significant opportunities for field teams to engage with physicians using fresh data [56] Question: What feedback has been received from physicians regarding BREXAFEMME? - Positive feedback was reported, highlighting the ease of use, one-day dosing, and quick symptom relief [58] Question: What is the target coverage by the end of the year? - The current coverage is 109 million lives, with a target of 65% of the commercial universe by the end of 2023 [59] Question: What are the copay ranges for patients? - Copays range from $5 to $600, with the majority falling between $30 to $50, which is considered acceptable [73] Question: What is the expected timeline for data from the FURI and CARES studies? - Data from these studies is expected in 2024, with the aim to wrap up activities in the first half of next year [66] Question: How is the company addressing the competition from Mycovia's product? - Management noted that Mycovia's product has a restricted label, which could benefit BREXAFEMME by highlighting its advantages [84]